CBD and alcohol use disorder have become an increasingly discussed pairing in recent years. Now, two new randomised controlled trials suggest cannabidiol simply does not outperform a placebo in cutting alcohol consumption. The research appears in Alcohol: Clinical and Experimental Research, and the findings may surprise many people who have turned to CBD hoping it might ease their drinking.

Scientists at NYU Grossman School of Medicine led the work. They set out to test whether CBD could genuinely help adults struggling with alcohol use disorder, including those also living with post-traumatic stress disorder. The answer, they conclude, is probably not, at least at the doses tested.

What the CBD and Alcohol Use Disorder Trials Involved

Researchers pooled data from two simultaneous proof-of-concept trials involving 54 adult participants. All had moderate to severe alcohol use disorder. Participants in the second trial also carried a clinical diagnosis of PTSD or subthreshold PTSD, a combination that typically worsens outcomes for both conditions.

In the first trial, 25 participants received either 600 mg of CBD per day for four weeks, rising to 1,200 mg for a further four weeks, or an identical-looking placebo. The second trial enrolled 29 participants, all with co-occurring PTSD. They received 600 mg of CBD daily for six weeks or a placebo.

Neither the participants nor the clinical assessors knew who was taking CBD and who was taking an inactive capsule. The research team monitored adherence closely through pill counts and video recordings participants made on their mobile phones each time they took a dose.

Researchers tracked alcohol consumption weekly using the Timeline Followback method, a well-validated self-report tool. They also collected blood samples at multiple time points to measure actual CBD levels circulating in each participant’s system.

The Results: Everyone Improved, But CBD Made No Difference

This is where the findings get genuinely interesting. Participants in both groups, those taking CBD and those on placebo, reduced their drinking substantially. Drinks per day fell from roughly five before the study to around 2.6 during treatment. Heavy drinking days dropped from 53% to approximately 23%. Effect sizes for these within-group changes were large, with Cohen’s dz values consistently above 0.9 across both trials.

When researchers compared the two groups directly, though, CBD produced no meaningful advantage. It did not beat placebo on drinks per day, percentage of heavy drinking days, alcohol craving, anxiety, or depression. In the second trial, it also failed to reduce PTSD symptom severity.

One tentative signal did appear. Higher CBD blood levels showed a modest association with improved depression scores at four weeks. The researchers flag this as exploratory and urge caution. It is a post-hoc finding and does not change the overall picture.

Why Did the Placebo Group Improve So Much?

The strong improvement in the placebo group deserves attention. Several factors likely contributed. Participants attended frequent medical management visits, which provided structure and consistent professional support. Many also entered the trial drinking at relatively moderate levels for an AUD population, averaging around five drinks per day. That left less statistical room for further improvement.

This high placebo response rate is a recognised challenge in alcohol use disorder research. When participants in the inactive arm already improve substantially, detecting any additional benefit from an active treatment becomes very difficult, especially in small trials.

Was the Cannabidiol and Alcohol Use Disorder Dose High Enough?

The researchers openly question whether the doses they used were sufficient to achieve a real therapeutic effect. A separate 2024 human laboratory study showed a single 800 mg dose of CBD reduced alcohol craving and blunted brain responses to alcohol cues. The mean CBD blood level in that study reached 257 ng/mL. In these trials, the mean estimated peak level at four weeks on 600 mg per day was only 130.75 ng/mL, roughly half that figure.

When the first trial doubled the dose to 1,200 mg, blood levels rose to around 275 ng/mL, comparable to that craving study. Yet even then, CBD produced no clear benefit over placebo for alcohol consumption.

A further complication emerged. Participants with the highest CBD blood levels actually improved their drinking less than those with lower levels. Animal studies have reported a similar pattern, where CBD shows anxiolytic effects at moderate doses but loses effectiveness at higher ones. The researchers are careful not to over-interpret this, but it raises genuine questions about the optimal dose for treating cannabidiol and alcohol use disorder together.

Safety Profile: Generally Tolerable, With Some Caveats

CBD was generally well tolerated across both trials. Most adverse events were mild or moderate in severity. The most common side effects among CBD participants were diarrhoea (27%), somnolence (23%), and nausea (20%). Only nausea occurred at a significantly higher rate than in the placebo group.

Seven of the 31 participants taking CBD reduced or stopped their dose because of side effects. One participant in the first trial developed diabetic ketoacidosis 25 days after their final CBD dose. The individual had pre-existing diabetes. Researchers judged the event as possibly related to the study medication, given the known link between cannabis use and ketoacidosis risk in people with type 1 diabetes.

Researchers noted elevated liver enzymes in two CBD participants and one placebo participant. One case of suicidal ideation appeared in each treatment group. CBD is broadly safe at these doses, but it carries real risks, and its use needs monitoring, particularly at higher doses.

What CBD and Alcohol Use Disorder Research Means for People Seeking Help

For anyone hoping CBD might offer a straightforward way to cut down drinking, these findings serve as a clear reality check. The study adds to mounting evidence that the compound’s therapeutic benefits have been considerably overstated in popular discussion.

Several well-evidenced treatments for alcohol use disorder already exist. Approved medications include naltrexone, acamprosate, and disulfiram. Psychological approaches such as cognitive behavioural therapy, 12-step facilitation, and relapse prevention programmes carry strong track records. These remain the most reliably supported options for anyone concerned about their own drinking or that of someone close to them.

The study authors do not entirely dismiss future CBD research. They acknowledge that larger trials, different patient groups, more precise dosing, and formulations that achieve higher blood levels might yet produce different results. On current evidence, however, they are clear. CBD cannot be recommended as a treatment for alcohol use disorder, or for the anxiety, depression, and PTSD that so often accompany it.

The hype around CBD and alcohol recovery has moved far ahead of the science. Until larger, better-powered trials provide more definitive answers, people seeking real support with alcohol use are far better served by treatments that already have the evidence behind them.

Source: dbrecoveryresources